NASDAQ: HRMYHarmony Biosciences Holdings Inc Stock
$33.76+0.27 (+0.81%)
Updated Dec 6, 2024
HRMY Price
$33.76
Fair Value Price
N/A
Market Cap
$1.93B
52 Week Low
$28.14
52 Week High
$41.61
P/E
15.7x
P/B
3.23x
P/S
3.34x
PEG
0.67x
Dividend Yield
N/A
Revenue
$681.88M
Earnings
$122.63M
Gross Margin
78.7%
Operating Margin
29.93%
Profit Margin
18%
Debt to Equity
0.56
Operating Cash Flow
$221M
Beta
0.93
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HRMY Overview
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HRMY's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
A
Value
C
Growth
C
Momentum
C
Sentiment
C
Safety
A
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
HRMY
Ranked#26 of 554
Ranked#26 of 554
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $25.45 | A | |
| $6.72 | A | |
| $19.82 | A |
Be the first to know about important HRMY news, forecast changes, insider trades & much more!
HRMY News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HRMY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HRMY ($33.76) is trading above its intrinsic value of $30.06, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HRMY is good value based on its earnings relative to its share price (15.7x), compared to the US market average (29.86x)
P/E vs Market Valuation
HRMY is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more HRMY due diligence checks available for Premium users.
Valuation
HRMY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
15.7x
Industry
-105.55x
Market
29.86x
HRMY is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
HRMY is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
HRMY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.23x
Industry
5.68x
HRMY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HRMY price to earnings growth (PEG)
For valuing profitable companies with growth potential
HRMY is good value based... subscribe to Premium to read more.
PEG Value Valuation
HRMY's financial health
Profit margin
Revenue
$186.0M
Net Income
$46.1M
Profit Margin
24.8%
HRMY's Earnings (EBIT) of $204.06M... subscribe to Premium to read more.
Interest Coverage Financials
HRMY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$928.1M
Liabilities
$331.3M
Debt to equity
0.56
HRMY's short-term assets ($522.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HRMY's short-term assets ($522.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HRMY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$70.5M
Investing
$745.0k
Financing
-$1.2M
HRMY's operating cash flow ($220.92M)... subscribe to Premium to read more.
Debt Coverage Financials
HRMY vs Biotech Stocks
Harmony Biosciences Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.